Edition:
United Kingdom

People: Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

12.22HKD
22 Jun 2018
Change (% chg)

HK$-0.24 (-1.93%)
Prev Close
HK$12.46
Open
HK$12.46
Day's High
HK$12.52
Day's Low
HK$12.10
Volume
36,121,448
Avg. Vol
43,281,724
52-wk High
HK$13.93
52-wk Low
HK$4.33

Tse, Ping 

Mr. Tse Ping serves as Chief Executive Officer, Executive Director of the Company. He is the founder of the Company and now serves as the Chief Executive Officer of the Company. He is responsible for the overall operations of the Group. With more than 24 years of experience in investment and management in the pharmaceutical industry in the PRC, he is currently a director of CT Tianqing, NJCTT, Jiangsu Fenghai, Jiangsu Qingjiang, Qingdao Haier, Qingdao Chia Tai Haier Medicines Co., Ltd., Qingdao Heng Seng Tang Pharmacy Co., Ltd., and Beijing Tide. He is also a director of Shanghai Fortune World Development Co., Ltd., Tianjin Chiatai Feed Tech Co., Ltd., SYN Energy Technology Co., Ltd. and Chia Tai Oversea Chinese Realty Development Co., Ltd. He is also a nonexecutive director of Tianjin Binhai Teda Logistics (Group) Corporation Limited, the shares of which are listed on GEM Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”). Mr. Tse is still a director of Chia Tai Qingchunbao Pharmaceutical Co., Ltd. (“CTQ”), a council member of the Association of Pharmaceutical Biotechnology of China and an honorary professor of Shenyang University of Pharmacy. Within the contemporary pharmaceutical industry, with the leadership by Mr. Tse, Sino Biopharmaceutical Limited has a leading position in the markets of hepatitis medicines and the therapeutic segment of micro-sphere target sustained medicine. CT Tianqing, Beijing Tide and CTQ were ranked the top 100 profit-making enterprises under the National Pharmaceutical Industrial Statistics Annual Report. In November, 2005, the Company was awarded one of the “Best under 1 US Billion enterprises within the Asian Pacific Region” by Forbes Asia. At the first “Capital – Chinese Outstanding Enterprise Achievement Prize” campaign launched by the Capital Magazine, the Company was awarded the “Capital – Chinese Outstanding Pharmaceutical Group Prize” in May, 2006.

Basic Compensation

Total Annual Compensation, HKD 33,050,000
Restricted Stock Award, HKD --
Long-Term Incentive Plans, HKD --
All Other, HKD 18,000
Fiscal Year Total, HKD 33,068,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Y Y Tse

6,968,000

Ping Tse

33,068,000

Cheung Ling Cheng

4,142,000

Minggang Wang

--

Chun Ling Li

--

Hsin Tse

1,863,000
As Of  31 Dec 2016